NZ612673A - Methods and composition for diagnosis and prognosis of renal injury and renal failure - Google Patents

Methods and composition for diagnosis and prognosis of renal injury and renal failure

Info

Publication number
NZ612673A
NZ612673A NZ612673A NZ61267310A NZ612673A NZ 612673 A NZ612673 A NZ 612673A NZ 612673 A NZ612673 A NZ 612673A NZ 61267310 A NZ61267310 A NZ 61267310A NZ 612673 A NZ612673 A NZ 612673A
Authority
NZ
New Zealand
Prior art keywords
event
measured concentration
threshold
likelihood
renal
Prior art date
Application number
NZ612673A
Other languages
English (en)
Inventor
Paul Mcpherson
Joseph Anderberg
Jeff Gray
James Patrick Kampf
Kevin Nakamura
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of NZ612673A publication Critical patent/NZ612673A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/7452—Thrombomodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ612673A 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure NZ612673A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24400009P 2009-09-18 2009-09-18
US24399509P 2009-09-18 2009-09-18
US25463609P 2009-10-23 2009-10-23
NZ598741A NZ598741A (en) 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample

Publications (1)

Publication Number Publication Date
NZ612673A true NZ612673A (en) 2014-10-31

Family

ID=43759017

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ612673A NZ612673A (en) 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure
NZ598741A NZ598741A (en) 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ598741A NZ598741A (en) 2009-09-18 2010-09-17 Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample

Country Status (10)

Country Link
US (2) US20130045494A1 (https=)
EP (2) EP2470904A4 (https=)
JP (3) JP2013513086A (https=)
CN (2) CN102576012B (https=)
AU (2) AU2010295512B2 (https=)
CA (1) CA2773905A1 (https=)
EA (1) EA201290106A1 (https=)
MX (1) MX2012003168A (https=)
NZ (2) NZ612673A (https=)
WO (1) WO2011035097A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2748605T (pt) * 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US20160147958A1 (en) * 2013-07-26 2016-05-26 Koninklijke Philips N.V. Computerization and visualization of clinical rules and definitions for patient monitoring systems
GB201501597D0 (en) * 2015-01-30 2015-03-18 Randox Lab Ltd Thrombomodulin
JP6232689B2 (ja) 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
US20190033325A1 (en) * 2016-01-29 2019-01-31 Advanced Telecommunications Research Institute International Renal function evaluating device, device for predicting onset of kidney disease complications, and phosphorous ingestion amount estimating device
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
JPH0736019B2 (ja) * 1989-12-27 1995-04-19 富士薬品工業株式会社 新規な抗ヒトトロンボモジュリンモノクローナル抗体によるヒトトロンボモジュリンおよびその分解産物の定量方法
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6544761B2 (en) * 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
CN1495258A (zh) * 1994-12-13 2004-05-12 人体基因组科学有限公司 金属蛋白酶-4的人组织抑制剂
CN1129666C (zh) * 1994-12-13 2003-12-03 人体基因组科学有限公司 金属蛋白酶－4的人组织抑制剂
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
WO2001042438A2 (en) * 1999-12-13 2001-06-14 Regents Of The University Of Minnesota Leukolysin/mmp25/mt6-mmp
AU2002227365A1 (en) * 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
WO2003006989A1 (fr) * 2001-07-12 2003-01-23 Kyowa Medex Co., Ltd. Procede de quantification de lipoproteines denaturees, reactifs pour la quantification de lipoproteines denaturees, procede de detection de maladies du systeme circulatoire et reactifs pour la detection de maladies du systeme circulatoire
CN1972703A (zh) * 2004-03-30 2007-05-30 丹麦皇家兽医和农业学院 通过阻断和检测蛋白酶抑制剂改进癌症的治疗和癌症治疗效率的预测
US7713693B1 (en) * 2004-09-01 2010-05-11 University Of Louisiana At Monroe Human cancer cell specific gene transcript
US20060160112A1 (en) * 2004-12-02 2006-07-20 Erdal Cavusoglu Tissue inhibitor of metalloproteinase (TIMP) as a marker and predictor of cardiovascular disease and both cardiac and non-cardiac mortality
US20090178145A1 (en) * 2005-05-11 2009-07-09 The Procter & Gamble Company Methods and targets for identifying compounds for regulating angiogenesis
WO2007053610A2 (en) * 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
JP2007163151A (ja) * 2005-12-09 2007-06-28 Kitasato Gakuen 対象生物の生理状態を判定する方法
CN101490273A (zh) * 2006-05-09 2009-07-22 南卡罗来纳州医科大学研究发展基金会 利用蛋白酶和蛋白酶抑制剂血浆分析检测舒张期心力衰竭
MX2008014155A (es) * 2006-05-09 2009-02-25 Musc Found For Res Dev Deteccion de insuficiencia cardiaca diastolica por proteasa y determinacion de perfil plasmatico de inhibidor de proteasa.
WO2008084331A2 (en) * 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
US8445222B2 (en) * 2006-07-11 2013-05-21 Musc Foundation For Research Development Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling
GB0617429D0 (en) * 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
WO2008060607A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
FR2909180B1 (fr) * 2006-11-29 2009-02-20 Diagnostica Stago Soc Par Acti Methode de mesure fonctionnelle de l'activite de la thrombomoduline plasmatique.

Also Published As

Publication number Publication date
CN102576012B (zh) 2015-07-15
JP6403712B2 (ja) 2018-10-10
CN105004864A (zh) 2015-10-28
JP2013513086A (ja) 2013-04-18
JP2015129764A (ja) 2015-07-16
MX2012003168A (es) 2012-05-08
EP2470904A4 (en) 2013-05-01
CN105004864B (zh) 2017-11-03
EP2470904A1 (en) 2012-07-04
JP2016176953A (ja) 2016-10-06
US20190250170A1 (en) 2019-08-15
HK1167889A1 (zh) 2012-12-14
WO2011035097A1 (en) 2011-03-24
NZ598741A (en) 2013-07-26
US20130045494A1 (en) 2013-02-21
AU2015200953A1 (en) 2015-03-12
HK1212774A1 (zh) 2016-06-17
AU2010295512B2 (en) 2014-12-18
AU2010295512A1 (en) 2012-04-05
CN102576012A (zh) 2012-07-11
CA2773905A1 (en) 2011-03-24
EP3299821A1 (en) 2018-03-28
EA201290106A1 (ru) 2012-12-28

Similar Documents

Publication Publication Date Title
NZ700695A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594771A (en) Methods and compositions for diagnosis and prognosis of renal injury and failure
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624609A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628843A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ600160A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ604873A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ619918A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ608384A (en) Biomarkers of renal injury
NZ630621A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ612673A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure
NZ598034A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2014CN01787A (https=)
TR201903235T4 (tr) Böbrek hasari ve böbrek yetmezli̇ği̇ni̇n tanilanmasi ve prognozuna yöneli̇k metotlar ve bi̇leşi̇mler.
NZ601648A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP1989551A4 (en) METHOD OF DETECTING OR DIAGNOSING NEURODEGENERATIVE DISEASE OR DISEASE
WO2011021041A3 (en) Survival prognostic assay

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 SEP 2017 BY FB RICE

Effective date: 20150203

LAPS Patent lapsed